Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTKB Stock Forecast 2025-2026
$2.45
Current Price
$310.31M
Market Cap
Buy 2
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to CTKB Price Targets
+267.3%
To High Target of $9.00
+63.3%
To Median Target of $4.00
+22.4%
To Low Target of $3.00
CTKB Price Momentum
-8.2%
1 Week Change
-35.9%
1 Month Change
-58.9%
1 Year Change
-62.2%
Year-to-Date Change
-67.9%
From 52W High of $7.63
+2.5%
From 52W Low of $2.39
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cytek (CTKB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CTKB and similar high-potential opportunities.
Latest CTKB Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CTKB has a neutral consensus with a median price target of $4.00 (ranging from $3.00 to $9.00). The overall analyst rating is Buy (6.7/10). Currently trading at $2.45, the median forecast implies a 63.3% upside. This outlook is supported by 2 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Mason Carrico at Stephens & Co., projecting a 267.3% upside. Conversely, the most conservative target is provided by Matthew Sykes at Goldman Sachs, suggesting a 22.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTKB Analyst Ratings
2
Buy
3
Hold
1
Sell
CTKB Price Target Range
Low
$3.00
Average
$4.00
High
$9.00
Current: $2.45
Latest CTKB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTKB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $3.00 |
| Mar 19, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $6.00 |
| Mar 4, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $8.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $8.50 |
| Aug 13, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $8.00 |
| May 13, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $8.50 |
| Mar 6, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $10.00 |
| Feb 29, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $10.00 |
| Dec 14, 2023 | Stephens & Co. | Mason Carrico | Overweight | Initiates | $9.00 |
| Nov 9, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $7.00 |
| Oct 24, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $8.00 |
| Oct 16, 2023 | Piper Sandler | David Westenberg | Overweight | Maintains | $10.00 |
| Jul 19, 2023 | Raymond James | Andrew Cooper | Market Perform | Initiates | $0.00 |
| May 11, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $13.00 |
| May 10, 2023 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $12.00 |
| Mar 7, 2023 | Piper Sandler | David Westenberg | Overweight | Maintains | $15.00 |
| Mar 2, 2023 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $14.00 |
| Mar 2, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $14.00 |
| Aug 18, 2022 | Piper Sandler | David Westenberg | Overweight | Maintains | $16.00 |
| Aug 12, 2022 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $15.00 |
Cytek Biosciences Inc. (CTKB) Competitors
The following stocks are similar to Cytek based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytek Biosciences Inc. (CTKB) Financial Data
Cytek Biosciences Inc. has a market capitalization of $310.31M with a P/E ratio of 374.5x. The company generates $197.05M in trailing twelve-month revenue with a -5.7% profit margin.
Revenue growth is -7.6% quarter-over-quarter, while maintaining an operating margin of -36.1% and return on equity of -2.9%.
Valuation Metrics
Market Cap
$310.31M
Enterprise Value
$64.40M
P/E Ratio
374.5x
PEG Ratio
40.8x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
-7.6%
Gross Margin
+48.6%
Operating Margin
-36.1%
Net Margin
-5.7%
EPS Growth
-7.6%
Financial Health
Cash/Price Ratio
+85.6%
Current Ratio
5.6x
Debt/Equity
4.2x
ROE
-2.9%
ROA
-3.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cytek Biosciences Inc. (CTKB) Business Model
About Cytek Biosciences Inc.
What They Do
Develops innovative flow cytometry technologies.
Business Model
The company generates revenue by developing and delivering advanced flow cytometry systems and products tailored for researchers and clinicians in the life sciences. These products enable high-parameter cell analysis, which is essential for drug discovery, clinical trials, and personalized medicine, thereby driving sales in various biotechnology sectors.
Additional Information
Cytek Biosciences Inc. is positioned as a key player in the biotechnology market, significantly impacting fields such as immunology and oncology. Its technology enhances the accuracy and efficiency of cellular analysis, supporting scientific discoveries and public health initiatives.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
676
CEO
Dr. Wenbin Jiang Ph.D.
Country
United States
IPO Year
2021
Website
cytekbio.comCytek Biosciences Inc. (CTKB) Latest News & Analysis
Latest News
Quick Summary
Cytek Biosciences, Inc. (NASDAQ:CTKB) will hold its Q1 2025 earnings conference call on May 8, 2025, at 4:30 PM ET, featuring executives and analysts from various firms.
Why It Matters
Cytek Biosciences' earnings call will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences (Nasdaq: CTKB) reported its Q1 financial results for 2025 on May 8, 2025. Further details on performance were not provided in the excerpt.
Why It Matters
Cytek Biosciences' Q1 financial results can signal growth potential, operational efficiency, and future profitability, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences (CTKB) reported a quarterly loss of $0.09 per share, worse than the expected loss of $0.04, compared to a loss of $0.05 per share in the same quarter last year.
Why It Matters
Cytek's larger-than-expected quarterly loss signals potential operational challenges, which may impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?
18 days ago
Quick Summary
Cytek is considered undervalued by 16.43% to 109.37%. In 2024, it reported net losses with operating expenses at 65.67% of sales, $277.86M in cash, and $103.76M in total liabilities.
Why It Matters
Cytek's significant undervaluation suggests potential upside for investors, despite current losses linked to growth strategies. Strong cash reserves indicate financial stability amid high operating expenses.
Source: Seeking Alpha
Market Sentiment:
Positive
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
24 days ago
Quick Summary
Cytek Biosciences is presenting its Full Spectrum Profilingâ„¢ technology at CYTO 2025 and AAI's IMMUNOLOGY2025 events.
Why It Matters
Cytek's technology showcase at key industry events highlights innovation potential, which could drive future sales growth and enhance market position, influencing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences reported a 77% YoY increase in FY2024 adjusted EBITDA, indicating strong profitability. Despite a 41% YTD stock decline, growth drivers suggest positive future prospects.
Why It Matters
Cytek Biosciences shows strong profitability potential with a 77% EBITDA increase and effective cost management, despite a stock decline, indicating potential upside for future growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CTKB Stock
What is Cytek Biosciences Inc.'s (CTKB) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Cytek Biosciences Inc. (CTKB) has a median price target of $4.00. The highest price target is $9.00 and the lowest is $3.00.
Is CTKB stock a good investment in 2025?
According to current analyst ratings, CTKB has 2 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTKB stock?
Wall Street analysts predict CTKB stock could reach $4.00 in the next 12 months. This represents a 63.3% increase from the current price of $2.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytek Biosciences Inc.'s business model?
The company generates revenue by developing and delivering advanced flow cytometry systems and products tailored for researchers and clinicians in the life sciences. These products enable high-parameter cell analysis, which is essential for drug discovery, clinical trials, and personalized medicine, thereby driving sales in various biotechnology sectors.
What is the highest forecasted price for CTKB Cytek Biosciences Inc.?
The highest price target for CTKB is $9.00 from Mason Carrico at Stephens & Co., which represents a 267.3% increase from the current price of $2.45.
What is the lowest forecasted price for CTKB Cytek Biosciences Inc.?
The lowest price target for CTKB is $3.00 from Matthew Sykes at Goldman Sachs, which represents a 22.4% increase from the current price of $2.45.
What is the overall CTKB consensus from analysts for Cytek Biosciences Inc.?
The overall analyst consensus for CTKB is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are CTKB stock price projections?
Stock price projections, including those for Cytek Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:07 PM UTC